Can CML patients responding positively to therapy have their medications safely reduced? CML expert Dr. Mhairi Copland of the University of Glasgow reports the findings from a clinical trial studying the safety of reducing tyrosine kinase inhibitor (TKI) therapy in patients with CML. Tune in to learn when dosage reduction may be appropriate.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement